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Familial amyotrophic lateral sclerosis (FALS) affects 5%–10% of cases of amyotrophic lateral sclerosis (ALS) and
is inherited as an autosomal dominant condition with incomplete penetrance. One-fifth of these cases of FALS are
associated with mutations in copper/zinc-dependent superoxide dismutase (SOD1), but the gene defect in the
remaining 80% of familial cases is, as yet, unknown. We have carried out a preliminary genome screen, using a
U.K. resource of families lacking SOD1 mutations, to identify other potential disease loci and have identified a
putative locus on chromosome 16q12.1-q12.2. The region associated with disease was further refined in the major
family that contributed to this result and was localized to D16S409–D16S3032, a 14.74-cM genetic interval that
corresponds to a physical distance of 6.6 Mb, which coincides with a region independently identified by two further
research groups in the United States and the United Kingdom.
Amyotrophic lateral sclerosis (ALS) is a late-onset, severe,
debilitating condition that affects spinal cord, brain stem,
and cortical motor neurons; causes progressive muscle
weakness, atrophy, and paralysis; and leads finally to res-
piratory failure. There have been considerable advances
in the understanding of disease progression from studies
on the dominantly inherited familial form of ALS (fa-
milial amyotrophic lateral sclerosis [FALS]), which, al-
though rare (accounting for 5%–10% of cases), is clin-
ically indistinguishable from the sporadic form of the
disease. Approximately 20% of FALS cases have been
shown to be associated with mutations in copper/zinc-
dependent superoxide dismutase (SOD1) (Rosen et al.
1993), designated “ALS1” (MIM 147450), and this has
provided much insight into potential mechanisms of
pathogenesis (Beckman et al. 2001; Cleveland and Roth-
stein 2001).
A second adult-onset locus has recently been reported
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in a single pedigree by Hand et al. (2002), which is
designated “ALS3” (MIM 606640) and localizes to a
7.5-cM region on chromosome 18q21. A slowly pro-
gressing autosomal dominant form of ALS with juvenile
onset, designated “ALS4” (MIM 602433), has been
mapped to chromosome 9q34 by Chance et al. (1998)
and further localized to a 500-kb interval by Blair et al.
(2000). A dominant form of ALS with frontotemporal
dementia (ALSFTD [MIM 105550]) has also been de-
scribed, which localizes to chromosome 9q21-q22 (Hos-
ler et al. 2000). In addition to these dominantly inherited
forms of ALS, autosomal recessive forms are known. A
rare autosomal recessive form of juvenile-onset ALS,
“ALS2” (MIM 606352), maps to chromosome 2q33
(Hentati et al. 1994), and the gene mutated in these
families has been identified as a GTPase, termed “alsin”
(Hadano et al. 2001; Yang et al. 2001). The most preva-
lent recessive form of ALS with juvenile onset, FALS5
(MIM 602099) has been mapped to chromosome
15q15-q22 (Hentati et al. 1998).
However, the majority (∼80%) of adult-onset domi-
nantly inherited FALS cases cannot be attributed to any
of these loci and remain to be elucidated. With this elu-
cidation as our major goal, we have carried out a genome
screen in our 13 most extensive U.K. families that lack
SOD1 mutations (de Belleroche et al. 1996; Orrell et al.
1997). Further heterogeneity is indicated from this analy-
384 Am. J. Hum. Genet. 73:383–389, 2003
sis, as data have been obtained that are suggestive of
several putative loci present in separate family subsets.
One such subset, where heterogeneity was confirmed by
use of HOMOG version 3.33, contains three families and
shows a significant association between chromosome-16
markers (D16S409 and D16S3032) and disease (multi-
point LOD score of 3.16 obtained from the summation
of LOD scores [SIMWALK2 version 2.82] for three fami-
lies at D16S3035). In this report, we describe the major
family (MB2) that contributes to this LOD score, local-
izing the region to a 14.74-cM interval and a physical
distance of 6.6 Mb (National Center for Biotechnology
Information [NCBI]). Independently, two other labo-
ratories have described three further families with FALS
that map to the same region and show an overlap of
9.42 cM.
A diagnosis of ALS was confirmed clinically in the
index case (fig. 1; individual 5.10), with evidence of both
upper and lower motor–neuron involvement, by use of
the El Escorial criteria for diagnosis of ALS (Brooks
1994). Bulbar signs were also present. The patient pre-
sented with lower limb weakness. The age at onset was
37 years, and the duration of illness was 36 mo. A less-
rapid disease progression was seen in other affected family
members, with disease duration lasting up to 20 years.
The average age at onset for four affected individuals
was 50.25 years (range 37–66 years). No SOD1 muta-
tions were detected in the five exons of SOD1. This study
has been approved by the Riverside Research Ethics
Committee (Hammersmith Hospitals National Health
Service Trust), with appropriate informed consent from
subjects.
Simulation calculations, by use of SIMLINK version
4.12 (Ploughman and Boehnke 1989), were used to de-
tect the statistical power of this family to detect genetic
linkage and resulted in a theoretical two-point LOD score
of 3.791 at , which demonstrated the statisticalvp 0
power of this family and, hence, the feasibility of using
this family for further study.
DNA was extracted from whole blood or the buffy coat
layer, by use of a Qiagen Blood and Tissue DNA ex-
traction kit according to the manufacturer’s instructions,
except for the elution of the DNA from the spin columns,
which was performed in 200 ml distilled H2O instead of
the Qiagen elution buffer. Following an initial genome
screen, by use of the Human Genome Mapping Project
(HGMP) linkage mapping set markers, a subset of fami-
lies indicated putative linkage to chromosome 16. Further
mapping of chromosome 16 was performed by use of a
total of 43 microsatellite markers, fluorescently labeled
with either FAM, HEX, TET, or NED fluorochromes (for-
ward primer only), which spanned a region of 100.76 cM
from D16S423 to D16S422 on chromosome 16, by use
of published sequence data. The order of the microsatellite
markers was determined according to the Marshfield ge-
netic map of chromosome 16. PCRs were performed by
use of Platinum Taq DNA polymerase (Invitrogen), ac-
cording to the manufacturer’s instructions. PCR samples
were pooled together on the basis of expected size and
fluorescent label used. Electrophoresis of the pooled
samples was then performed on the ABI 310 Genetic
Analyzer. Information concerning peak size of products,
allele assignment, and allele frequency was determined
by use of the ABI software package Genotyper version
2.5.
Two-point linkage analysis of genotyping data was
performed by use of the MLINK program (version 5.1)
of the FASTLINK version 4.1p software package. In-
dividuals confirmed clinically with FALS were entered
as “affected status,” and unaffected individuals at risk
of disease, aged80 years, were entered as “unaffected
status.” Penetrance curves were not used, since no indi-
viduals of unknown status (other than obligate carriers)
were entered into the analysis. The analysis was per-
formed by use of the model that FALS was inherited in
an autosomal dominant manner. The frequency of the
mutant allele was taken as 0.0001. Simple counting es-
timates were used to determine marker allele frequencies
from at least 52 individuals. Marker D16S419 has been
omitted from the analysis, since its chromosomal posi-
tion is unsure. Multipoint analysis on the same data was
performed initially by use of Genehunter 2.1 r3 and,
subsequently, by use of the SIMWALK2 version 2.82
software package. Haplotype reconstruction was initially
performed manually and confirmed by use of the haplo-
type function of SIMWALK2 version 2.82.
Following a genome screen on 13 U.K. families with
FALS, a putative locus was indicated on chromosome 16
(16q12.1-16q12.2) in a subset of families. The major
family linked to this region was characterized by a domi-
nantly inherited form of ALS that was evident in three
generations. DNA was available from 10 individuals from
two generations; 4 individuals were affected, and partial
reconstructions of the genotypes of 4 further individuals
have been performed (fig. 1). The affected individuals in
this family lacked mutations in all exons of SOD1, and
significant exclusion of linkage to ALS2, ALS3, and
ALS4 was obtained by use of close markers for these
loci. For ALS2, three markers within 7 cM of alsin were
used (LOD scores and Marshfield genetic distances, where
available, are shown in parentheses): D2S115 (LODp
; 195.65 cM), D2S309 ( ; 198.652.981 LODp 4.367
cM), and D2S155 ( ; 202.92 cM). ForLODp 3.746
the ALS3 locus, which is flanked by D18S846 (77.36
cM) and D18S1109 (84.8 cM), two markers were used:
D18S57 ( ; 62.85 cM) and D18S64LODp 0.71
( ; 84.8 cM). For ALS4 (9q34), the fol-LODp 4.34
lowing markers, reported by Blair et al. (2000), were
used: D9S159 ( ; 142.07 cM), D9S118LODp 3.782
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Figure 2 Multipoint linkage analysis of chromosome 16, generated by use of the SIMWALK2 version 2.82 software package
( ), and D9S1847 ( ;LODp 5.890 LODp 1.112
144.67 cM).
We have screened this family with 43 markers on chro-
mosome 16 and refined the region of linkage (fig. 2).
Recombinations in this family defined a region (16q12.1-
16q12.2), flanked by the markers D16S409 and
D16S3032, in which a common haplotype is shared by
affected individuals (fig. 1). There were no positive LOD
scores 10.87 obtained for this family from the genome
scan of chromosomes 1–15 and 17–22 by use of 344
markers (fig. 3). The marker alleles shared in the disease
haplotype (fig. 1) are D16S3080, D16S411, D16S3035,
D16S3136, D16S416, D16S770, D16S415, D16S3137,
and D16S771 (by use of Marshfield map distances and
markers ordered at the same distance, on the basis of
physical map data). The genetic distance flanked by
markers D16S409 (58.46 cM) and D16S3032 (73.20 cM)
is 14.74 cM, which approximates to a physical distance
of 6.6 Mb (NCBI). The maximum two-point LOD score
obtained by use of MLINK was 1.509 for D16S411 at
(table 1), and the multipoint analysis (fig. 2)v p 0
yielded maximum multipoint LOD scores, for markers
D16S3080 and D16S411, of 2.06 ( ).P ! .04
The region defined by the flanking markers contains
35 known genes, on the basis of SWISS-PROT, TrEMBL,
mRNA, and ResSeq data and 138 gene predictions (UCSC
Figure 3 A genome screen of family MB2 for chromosomes 1–15 and 17–22, by use of a total of 301 microsatellite markers. The multipoint
linkage analysis was performed by use of Genehunter version 2.1r3 software. The numbers of microsatellite markers for each chromosome were
18, 18, 9, 18, 11, 52, 18, 17, 8, 7, 14, 33, 7, 11, 10, 12, 11, 4, 9, 9, and 5, respectively.
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Table 1
Two-Point LOD Scores for Family with FALS on
Chromosome 16q12.1-q12.2
Locusa
vp
.0 .1 .2 .3 .4
D16S420  .375 .150 .054 .012
D16S3100 .172 .096 .048 .021 .007
D16S3022  .713 .290 .114 .033
D16S261 .488 .288 .144 .059 .018
D16S3105 .626 .425 .252 .121 .039
D16S3044 .083 .069 .043 .010 .008
D16S409  .096 .019 .024 .022
D16S477 .067 .042 .024 .010 .002
D16S517 .122 .091 .049 .018 .002
D16S3080 1.192 .902 .619 .362 .148
D16S411 1.509 1.079 .664 .315 .091
D16S3035 .965 .710 .456 .226 .067
D16S3136 .512 .335 .199 .102 .036
D16S416 .537 .383 .252 .141 .052
D16S770 .618 .398 .234 .114 .033
D16S2623 .156 .212 .160 .086 .026
D16S415 1.045 .787 .533 .300 .112
D16S3034 .162 .208 .154 .081 .025
D16S3137 .562 .370 .214 .102 .034
D16S771 .487 .344 .203 .080 .006
D16S3032  .100 .007 .008 .006
D16S3112 .295 .066 .016 .007 .007
NOTE.—The two-point LOD scores were calculated by use
of the MLINK program.
a Loci are listed from pter (top of column) to qter (bottom
of column).
Genome Browser version 17). Several of the known genes
present in the region are expressed in the CNS and, in
some cases, possess properties relevant to cell viability
and, hence, potentially to ALS pathology: for example,
trinucleotide repeat containing 9 (TNRC9) (in view of
the important role of trinucleotide repeat expansions in
many late-onset neurodegenerative conditions), caspase
recruitment domain family (CARD15), and bromo-
domain-containing 7 (BRD7), which interacts with acety-
lated-histone peptides and affects transcriptional activa-
tion. In addition, several genes that encode transcription
factors and are involved in development are also present
in this region: for example, OLF-1/EBF associated zinc–
finger gene (OAZ), topoisimerase-related function protein
(TRF4–2), naked cuticle homolog 1 (Drosophila)
(NKD1), a putative zinc finger transcription factor Sal-
like 1 (Drosophila) (SALL1), retinoblastoma-like 2
(RBL2), and Iroquois homeobox proteins 5, 3, and 6
(IRX3, 5, and 6). Two further genes with a role in CNS
signaling are also present: cerebellin 1 precursor (CBLN1)
and adenylyl cyclase 7 (ADCY7).
Three further chromosome 16–linked families have
been identified independently: an American family under
investigation by Dr. R. Brown, a further U.K. family that
is in collaboration with Dr. Chris Shaw, and a Dutch
family that is being studied by Drs. Chris Shaw and Frank
Baas. For all four families, a common region of overlap
has been obtained between D16S3396 and D16S3032,
which covers a region of 9.42 cM (R. H. Brown and C.
Shaw, personal communications). We have initiated a
collaboration to facilitate this research. Our current plan
is to refine this region optimally with further markers
and then to embark on sequencing the genes in the re-
gion. The small size of this region and the availability,
through collaboration, of other linked families supports
the feasibility of identifying the putative disease gene
present at this locus. Subsequently, mutation analysis
will be performed on other cohorts of case subjects with
FALS, including the 190 U.K. families available at Char-
ing Cross Hospital.
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